• Japanese
  • Korean
  • Chinese
Cover Image

Global Vaccine Market Outlook 2020

The pharmaceutical segment has faced diminishing prospects because of declining research and development productivity, stringent regulatory activities and generic competition for off patent products. On the contrary, vaccine segment has developed as highly profitable because of advancements in genomics and manufacturing technologies as well as increasing demand from emerging economies.

Meanwhile, continuous efforts have been put in by the biopharmaceutical companies to create tremendous opportunities for leading players to tap this market. Besides, vaccines have high entry barrier for generic players and potential to generate blockbuster sales, which thereby allure the market players.

The report, "Global Vaccine Market Outlook 2020" provides an extensive research and in-depth analysis of the current status and future outlook of the global vaccine market. The market, which stood at US$ 30.5 Billion in 2013, is expected to grow at a CAGR of around 12% during 2013-2020.

In our report, we have segmented the global vaccine market based on 16 therapeutic categories, and market for each has been forecasted. For each therapeutic segment, marketed product portfolio, pipeline products along with recent developments have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the vaccines already in Phase III trials. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth.

In the end, various key players have been enlisted. Our team has analyzed each company's strengths and weaknesses along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Vaccine Market Outlook to 2020

4. Major Vaccines: Current and Future Market Analysis

  • 4.1 Pneumococcal
  • 4.2 Influenza
  • 4.3 Cancer
  • 4.4 Polio
  • 4.5 Varicella
  • 4.6 Rotavirus
  • 4.7 Meningococcal
  • 4.8 DTP
  • 4.9 Hepatitis
  • 4.10 Measles, Mumps, and Rubella (MMR)
  • 4.11 Japanese Encephalitis
  • 4.12 Tuberculosis
  • 4.13 Malaria
  • 4.14 Rabies
  • 4.15 Typhoid
  • 4.16 HIV

5. Key Geographical Markets

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China
  • 5.5 India
  • 5.6 Brazil

6. Pipeline Analysis

7. Competitive Landscape

  • 7.1 GSK
    • 7.1.1 Business Overview
    • 7.1.2 Vaccine Portfolio & Pipeline
    • 7.1.3 Strengths and Weaknesses
  • 7.2 Sanofi-Pasteur
    • 7.2.1 Business Overview
    • 7.2.2 Vaccine Portfolio & Pipeline
    • 7.2.3 Strengths and Weaknesses
  • 7.3 Pfizer
    • 7.3.1 Business Overview
    • 7.3.2 Vaccine Portfolio & Pipeline
    • 7.3.3 Strengths and Weaknesses
  • 7.4 Merck
    • 7.4.1 Business Overview
    • 7.4.2 Vaccine Portfolio & Pipeline
    • 7.4.3 Strengths and Weaknesses
  • 7.5 Novartis
    • 7.5.1 Business Overview
    • 7.5.2 Vaccine Portfolio & Pipeline
    • 7.5.3 Strengths and Weaknesses
  • 7.6 Emergent Biosolutions
    • 7.6.1 Business Overview
    • 7.6.2 Vaccine Portfolio & Pipeline
    • 7.6.3 Strengths and Weaknesses
  • 7.7 AstraZeneca Plc.
    • 7.7.1 Business Overview
    • 7.7.2 Vaccine Portfolio & Pipeline
    • 7.7.3 Strengths and Weaknesses
  • 7.8 Baxter International Inc.
    • 7.8.1 Business Overview
    • 7.8.2 Vaccine Portfolio & Pipeline
    • 7.8.3 Strengths and Weaknesses
  • 7.9 BioCSL (CSL Biotherapies)
    • 7.9.1 Business Overview
    • 7.9.2 Vaccine Portfolio & Pipeline
    • 7.9.3 Strengths and Weaknesses
  • 7.10 Dendreon Corporation
    • 7.10.1 Business Overview
    • 7.10.2 Vaccine Portfolio & Pipeline
    • 7.10.3 Strengths and Weaknesses
  • 7.11 Takeda Pharmaceutical Company Limited
    • 7.11.1 Business Overview
    • 7.11.2 Vaccine Portfolio & Pipeline
    • 7.11.3 Strengths and Weaknesses
  • 7.12 Crucell
    • 7.12.1 Business Overview
    • 7.12.2 Vaccine Portfolio & Pipeline
    • 7.12.3 Strengths and Weaknesses

List of Figures:

  • Figure 3-1: Global - Vaccine Market (Billion US$), 2013-2020
  • Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011
  • Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2013-2020
  • Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2013-2020
  • Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2013-2020
  • Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2013-2020
  • Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2013-2020
  • Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2013-2020
  • Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2013-2020
  • Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
  • Figure 4-10: Global - Number of nTetanus Incidences by Region (2009 & 2010)
  • Figure 4-11: Global - Number of tTetanus Incidences by Region (2009 & 2010)
  • Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
  • Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2013-2020
  • Figure 4-14: Global - Hepatitis Vaccine Market (Billion US$), 2013-2020
  • Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
  • Figure 4-16: Global - Number of Mumps Incidences by Region ('000), 2009 & 2010
  • Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
  • Figure 4-18: Global - MMR Vaccine Market (Million US$), 2013-2020
  • Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2013-2020
  • Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
  • Figure 5-1: Global - Vaccine Market by Region (%), 2013
  • Figure 5-2: Global - Vaccine Market by Region (%), 2020
  • Figure 5-3: US - Vaccine Market (Billion US$), 2013-2020
  • Figure 5-4: Europe - Vaccine Market (Billion US$), 2013-2020
  • Figure 5-5: Japan - Vaccine Market (Billion US$), 2013-2020
  • Figure 5-6: China - Vaccine Market (Billion US$), 2013-2020
  • Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2013)
  • Figure 5-8: India - Vaccine Market (Billion US$), 2013-2020
  • Figure 5-9: Brazil - Vaccine Market (Billion US$), 2013-2020
  • Figure 7-1: Global - Share of Key Players in Vaccine Market (2013)
  • Figure 7-2: GSK - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-3: GSK - Vaccine Revenue Breakup by Product (%), 2013
  • Figure 7-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2013
  • Figure 7-6: Pfizer - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2013
  • Figure 7-8: Merck - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2013
  • Figure 7-10: Novartis - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2013
  • Figure 7-12: Baxter International - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-13: BioCSL - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2013
  • Figure 7-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010

List of Tables:

  • Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
  • Table 4-2: Key Pneumococcal Vaccines in Pipeline
  • Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
  • Table 4-4: Key Influenza Vaccines in Pipeline
  • Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
  • Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
  • Table 4-7: Key Cancer Vaccines in Pipeline
  • Table 4-8: Polio Vaccine Market - Key Players and Vaccines
  • Table 4-9: Key Polio Vaccines in Pipeline
  • Table 4-10: Varicella Vaccine Market - Key Players and Vaccines
  • Table 4-11: Rotavirus Vaccine Market - Key Players and Vaccines
  • Table 4-12: Key Rotavirus Vaccines in Pipeline
  • Table 4-13: Meningococcal Vaccine Market - Key Players and Vaccines
  • Table 4-14: Key Meningococcal Vaccines in Pipeline
  • Table 4-15: DTP Vaccine Market - Key Players and Vaccines
  • Table 4-16: Key DTP Vaccines in Pipeline
  • Table 4-17: Hepatitis Vaccine Market - Key Players and Vaccines
  • Table 4-18: Key Hepatitis Vaccines in Pipeline
  • Table 4-19: MMR Vaccine Market - Key Players and Vaccines
  • Table 4-20: Key MMR Vaccines in Pipeline
  • Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines
  • Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
  • Table 4-23: Tuberculosis Vaccine Market - Key Players and Vaccines
  • Table 4-24: Key Tuberculosis Vaccines in Pipeline
  • Table 4-25: Key Malaria Vaccines in Pipeline
  • Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
  • Table 4-27: Key Rabies Vaccines in Pipeline
  • Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
  • Table 4-29: Key Typhoid Vaccines in Pipeline
  • Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
  • Table 4-31: Key HIV Vaccines in Pipeline
  • Table 5-1: China - Vaccine Classification
  • Table 6-1: Vaccine Pipeline Analysis
  • Table 7-1: GSK - Vaccines Portfolio
  • Table 7-2: GSK - Vaccines in Pipeline
  • Table 7-3: GSK - Strengths and Weaknesses
  • Table 7-4: Sanofi-Pasteur - Vaccines Portfolio
  • Table 7-5: Sanofi-Pasteur - Vaccines in Pipeline
  • Table 7-6: Sanofi-Pasteur - Strengths and Weaknesses
  • Table 7-7: Pfizer - Vaccines Portfolio
  • Table 7-8: Pfizer - Vaccines in Pipeline
  • Table 7-9: Pfizer - Strengths and Weaknesses
  • Table 7-10: Merck - Vaccines Portfolio
  • Table 7-11: Merck - Vaccines in Pipeline
  • Table 7-12: Merck - Strengths and Weaknesses
  • Table 7-13: Novartis - Vaccines Portfolio
  • Table 7-14: Novartis - Vaccines in Pipeline
  • Table 7-15: Novartis - Strengths and Weaknesses
  • Table 7-16: Emergent Biosolutions - Vaccines Portfolio
  • Table 7-17: Emergent Biosolutions - Vaccines in Pipeline
  • Table 7-18: Emergent Biosolutions - Strengths and Weaknesses
  • Table 7-19: AstraZeneca - Vaccines Portfolio
  • Table 7-20: AstraZeneca - Vaccines in Pipeline
  • Table 7-21: AstraZeneca - Strengths and Weaknesses
  • Table 7-22: Baxter International - Vaccines Portfolio
  • Table 7-23: Baxter International - Vaccines in Pipeline
  • Table 7-24: Baxter International - Strengths and Weaknesses
  • Table 7-25: BioCSL - Vaccines Portfolio
  • Table 7-26: BioCSL - Strengths and Weaknesses
  • Table 7-27: Dendreon Corporation - Vaccines Portfolio
  • Table 7-28: Dendreon Corporation - Vaccines in Pipeline
  • Table 7-29: Dendreon Corporation - Strengths and Weaknesses
  • Table 7-30: Takeda Pharmaceutical - Vaccines Portfolio
  • Table 7-31: Takeda Pharmaceutical - Vaccines in Pipeline
  • Table 7-32: Takeda Pharmaceutical - Strengths and Weaknesses
  • Table 7-33: Crucell - Vaccines Portfolio
  • Table 7-34: Crucell - Vaccines in Pipeline
  • Table 7-35: Crucell - Strengths and Weaknesses
Show More
Pricing